The company's drugs target tissue-specific hormone mechanisms to treat a range of gynecological conditions, including endometriotic lesions and polycystic ovarian syndrome. Their novel SERM, Fispemifene, offers new opportunities for treating male urological conditions and addressing unmet needs in women's and men's health. Forendo Pharma's therapeutic drugs are designed to assist medical professionals in improving the treatment of women's health indications.